Aptamer-Based C. difficile Toxin Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic tests for C. difficile infections are either cumbersome, require expensive equipment, or have modest sensitivity and specificity, limiting rapid and accurate diagnosis.
Innovation Solution
Development of aptamers that specifically bind to C. difficile toxins A, B, binary toxin A chain, and binary toxin B chain, enabling diagnostic kits and methods that include pull-down, dot blot, PCR, and sandwich assays for efficient toxin detection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current diagnostic tests for C. difficile are used, then diagnosis can be performed, but the tests are cumbersome, require expensive equipment, or have modest sensitivity and specificity
Solution Approach 1:
The patent replaces complex mechanical diagnostic systems (equipment-based tests) with a biochemical detection system using aptamers. The aptamers specifically bind to C. difficile toxins, enabling detection through simple binding assays rather than complex mechanical equipment, thereby improving diagnostic accuracy while reducing device complexity
Solution Approach 2:
The patent introduces aptamers as intermediary molecules that mediate between the C. difficile toxins and the detection system. These aptamers serve as highly specific binding agents that enable accurate toxin detection through simplified assay formats, resolving the contradiction between measurement precision and device complexity
2Reliability
If current diagnostic tests for C. difficile are used, then diagnosis can be performed, but the tests have modest sensitivity and specificity
Solution Approach 1:
The patent employs aptamers that have been pre-selected and optimized for high affinity and specificity to C. difficile toxins. This preliminary optimization of the binding reagents enables rapid and reliable detection without requiring complex confirmation steps, thereby improving diagnostic reliability while reducing the time lost in multi-step testing procedures
3Measurement precision
If aptamers are developed for C. difficile toxin detection, then sensitivity and specificity improve, but production and implementation costs must be evaluated
Solution Approach 1:
The patent utilizes aptamers which are nucleic acid-based molecules that can be synthesized chemically at lower cost compared to protein-based antibodies. These aptamers can be produced through in vitro selection methods (SELEX) and synthesized using standard oligonucleotide synthesis techniques, making them more economical and easier to manufacture while maintaining high detection sensitivity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The aptamers provide high specificity and sensitivity for detecting C. difficile toxins, reducing the need for expensive equipment and improving diagnostic accuracy and speed, while being cost-effective and easily producible.
Implementation Method 1
aptamers that specifically bind to C. difficile toxins A, B, binary toxin A chain, and binary toxin B chain
Data Source
AI summary
The present disclosure relates generally to the field of nucleic acids and, more particularly, to aptamers capable of binding to toxins produced by Clostridium difficile; diagnostic kits and methods comprising such aptamers; and methods of making and using such aptamers.